Trump Media & Technology Group, the parent company of Truth Social, announced a merger agreement with nuclear fusion company TAE Technologies in an all-stock deal valued at more than $6 billion. Upon ...

For a few brief weeks in September and October, Oracle was on top of the artificial-intelligence revolution. The storied business-software and database company had a burgeoning $300 billion ...

Oracle's debt is rising as cash flies out the door to fund AI data centers. The company already has a debt-heavy balance sheet, and it will need to borrow more to fund its AI infrastructure contracts.

US officials warn snowbirds of 'violent crime' in winter destination hot spot Coldplay kiss cam woman breaks silence - and she has a 'different version of this story' to tell NASCAR’s Greg Biffle and ...

A measure of Oracle Corp.’s credit risk climbed on Wednesday after the database company posted a jump in spending on data centers and other equipment, raising fresh doubts about how quickly it can ...

Oracle's cloud revenue growth may be cooling Oracle's adjusted profit boosted by $2.7 billion Ampere sale Oracle's future contracts rise 14.94% to $523 billion Shares fall 10% in extended trading Dec ...

Look at Oracle if you want to assess the sustainability of the AI investment boom: Its credit default swaps are emerging as a way to 'hedge the entire debt cycle within AI' For a few brief weeks in ...

A gauge of risk on Oracle Corp.’s debt reached a three-year high in November, and things are only going to get worse in 2026 unless the database giant is able to assuage investor anxiety about a ...

Within the modern interdependent economy, financial transactions have changed from a back-office activity to the foundation of business. For companies that span government, engineering, and life ...

An oracle is a person, usually possessing long-earned wisdom, that can share reliable information about the future. Oracle is a cloud-software company, now tied closely to the artificial intelligence ...

Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) ...